Abstract:Numerous molecular screening strategies have recently been developed to measure the chemical diversity of a population's biofluids with the ultimate aim to provide clinicians, medical scientists and epidemiologists with a clearer picture of the presence and severity of cardiovascular disease; prognosis; and response to treatment. Current cardiology practice integrates clinical history and examination with state-of-the-art imaging, invasive measures, and electrical interrogation. Biomarkers in common clinical use are relatively limited to troponin and brain natriuretic peptide, dependent on damage to heart muscle, or myocyte 'stretch' respectively. Although they have been recently applied to risk stratification in asymptomatic individuals at higher risk, the development of markers capable of detecting earlier phases of disease development would facilitate targeted strategies to prevent pathological complications in the general community. Metabolomics is the systematic study of small molecules in biological fluids. Profiling strategies aim to comprehensively measure and quantify such biomarkers in a fast, cost-effective and clinically informative manner. Techniques tend to be applied in an unbiased fashion, with advanced statistical methods allowing for identification of signature profiles in particular cohorts. In this manner, metabolomics has the potential to identify new pathophysiological pathways, and thus therapeutic targets, as well as assist in improved risk-stratification and personalized cardiovascular medicine. The latter has great potential in the primary and secondary cardiovascular disease prevention settings, integrating known and as yet unidentified host and environmental factors. The current review discusses applications of metabolomic techniques relevant to both the research and the clinical cardiologist.

Metabolomics: Implication in cardiovascular research and diseases

Translational and emerging clinical applications of metabolomics in cardiovascular disease diagnosis and treatment

Recent advances in cardiovascular disease research driven by metabolomics technologies in the context of systems biology

Narrative review of metabolomics in cardiovascular disease

Metabolic phenotyping and cardiovascular disease: an overview of evidence from epidemiological settings

Metabolomics and Lipidomics for Studying Metabolic Syndrome: Insights into Cardiovascular Diseases, Type 1 & 2 Diabetes, and Metabolic Dysfunction-Associated Steatotic Liver Disease

Proteomics and Metabolomics Combined in Cardiovascular Research

Recent advances in precision nutrition and cardiometabolic diseases

Metabolomics analysis for biomarker discovery: advances and challenges

Blood-Derived Lipid and Metabolite Biomarkers in Cardiovascular Research from Clinical Studies: A Recent Update

Metabonomics: a useful tool for the future surgeon

Identification of novel cardiovascular disease associated metabolites using untargeted metabolomics

Gut microbiome and its meta-omics perspectives: profound implications for cardiovascular diseases

Metabolomics meets lipidomics: Assessing the small molecule component of metabolism

Metabolomics for Clinical Biomarker Discovery and Therapeutic Target Identification

Biomarker identification and risk assessment of cardiovascular disease based on untargeted metabolomics and machine learning

Towards Metabolomic-Based Precision Approaches for Classifying and Treating Heart Failure

Exploring the Functional Roles of Small-Molecule Metabolites in Disease Research: Recent Advancements in Metabolomics

APPLICATION OF METABONOMICS IN CARDIOVASCULAR DISEASE RESEARCH

Emerging applications of metabolomics in clinical pharmacology

Novel Techniques, Biomarkers and Molecular Targets to Address Cardiometabolic Diseases